GRC 6211
Alternative Names: GRC-6211Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Analgesics
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain; Urinary incontinence
- Discontinued Dental pain; Neuropathic pain; Osteoarthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pain in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Urinary-incontinence in Europe (PO)
- 11 Feb 2011 Phase-I development is ongoing in Urinary incontinence